Warnex Extends Maturity Date of its Outstanding Debentures and Provides Update on its Listing Status
(firmenpresse) - LAVAL, QUEBEC -- (Marketwire) -- 03/02/12 -- Warnex Inc. (TSX: WNX) ("Warnex") is pleased to announce that Persistence Capital Partners LP ("PCP") has agreed to extend the maturity date of the two outstanding convertible debentures of Warnex that it holds in the aggregate principal amount of approximately $1,425,630 from February 29, 2012, to March 19, 2012.
In addition, Warnex announces that, as disclosed in a recent TSX Bulletin, the Toronto Stock Exchange (the "TSX") has agreed to extend the date of delisting of the Common Shares of Warnex from the TSX to the close of business on March 19, 2012. Warnex continues to explore its various options in light of this scheduled delisting.
About Warnex
Warnex () is a life sciences company devoted to protecting public health by providing laboratory services to the pharmaceutical sector. Warnex Analytical Services provides pharmaceutical and biotechnology companies with a variety of quality control services, including chemistry, chromatography, microbiology, method development and validation, and stability studies. Warnex Bioanalytical Services specializes in bioequivalence and bioavailability studies for clinical trials. Warnex has two facilities located in Laval and Blainville, Quebec.
CAUTION REGARDING FORWARD-LOOKING STATEMENTS
Certain statements contained in this news release are forward-looking and are subject to numerous risks and uncertainties, known and unknown. For further information identifying known risks and uncertainties, relating to financial resources, liquidity risk, key customers and business partners, credit risk, foreign currency risk, government regulations, laboratory facilities, volatility of share price, employees, suppliers, and other important factors that could cause actual results to differ materially from those anticipated in the forward-looking statements, please refer to the heading Risks and Uncertainties in Warnex's most recent Management's Discussion and Analysis, which can be found at . Consequently, actual results may differ materially from the anticipated results expressed in these forward-looking statements.
Contacts:
Michael Singer
Chairman of the Executive Committee
of the Board of Directors, Warnex Inc.
(514) 940-3610
Francois Jette
Chief Financial Officer
Warnex Inc.
(450) 663-6724 x 325
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 02.03.2012 - 14:32 Uhr
Sprache: Deutsch
News-ID 121101
Anzahl Zeichen: 0
contact information:
Town:
LAVAL, QUEBEC
Kategorie:
Biotech
Diese Pressemitteilung wurde bisher 249 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Warnex Extends Maturity Date of its Outstanding Debentures and Provides Update on its Listing Status"
steht unter der journalistisch-redaktionellen Verantwortung von
Warnex Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
